Concert has pioneered the use of deuterium (a hydrogen isotope) in medicinal chemistry and has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor that blocks Janus kinases JAK1 and JAK2 for the treatment of baldness. Concert has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe.

Leave a Reply

Your email address will not be published. Required fields are marked *